Response Evaluation Criteria in Solid Tumors (RECIST) is “a standard way to measure how well a cancer patient responds to treatment. It is based on whether tumors shrink, stay the same, or get bigger. To use RECIST, there must be at least one tumor that can be measured on x-rays, CT scans, or MRI scans. The types of response a patient can have are a complete response (CR), a partial response (PR), progressive disease (PD), and stable disease (SD).” (Source: National Cancer Institute)
Learn about the DTRF Radiomics Working Group RECIST is currently required by the FDA in clinical trials to assess if a tumor is progressing, stable, or responding to treatment, RECIST is strictly measurement-based and does not factor in other positive indicators that do not involve changes in tumor size. Additionally, RECIST relies on certain measurements to monitor response — such as “longest dimension” — which may not accurately reflect the typical response of desmoid tumors to treatments. The DTRF Radiomics Working Group[link to “Radiology Working Group” page] is addressing this issue and defining other imaging features beyond RECIST that can be used to better evaluate desmoid tumor patient outcomes.